AstraZeneca shares outperform market slump after upbeat Jefferies comments
Analysts argue drugmaker is ‘at a turning point’
Group flags rise in product sales this year
AstraZeneca remains ‘top pick’ for Barclays December 2017
Analysts upbeat on the Anglo-Swedish drugmaker’s pipeline
Deutsche Bank remains bullish on AstraZeneca December 2017
Analysts point to encouraging drug trial results
AstraZeneca warns of $35m hit from higher duty
Financial hit related to BrexitDecember 2017
AstraZeneca shares in demand after asthma drug approval
FDA endorses benralizumabNovember 2017
AstraZeneca lifts earnings guidance
Company reports receding impact from loss of exclusivityNovember 2017
FDA grants priority review status to AstraZeneca’s Imfinzi
Credit Suisse praises pharmco’s recent progressOctober 2017
Exane BNP Paribas turns bullish on AstraZeneca
Analysts point to ‘concentration of value’ in pipelineSeptember 2017
- More news
AstraZeneca share price in focus as Amgen ends psoriasis drug partnership
Amgen is ending its partnership with AstraZeneca to develop a psoriasis treatment after observing suicidal thoughts in patients in a trial.May 2015
AstraZeneca share price: Pharmco to invest $285m in biotech facility
AstraZeneca is investing $285 million in a biotech facility in Sweden.May 2015
AstraZeneca share price: Pharmco dives deeper into personalised healthcare
AstraZeneca inks two research deals which will see it explore the potential of personalised healthcare in heart and respiratory diseases.May 2015
drug maker receives EU approval for child flu vaccine
UK pharmaceutical giant mulls Forest Laboratories bid, sources sayDecember 2013
Analysts see drugmaker as viable takeover target
Improved Pfizer bid to negate US anti-inversion measures, Jefferies analysts sayOctober 2014
- More news
About AstraZeneca plc
AstraZeneca Plc (LON:AZN) is a British-Swedish multinational biopharmaceutical company, headquartered in London, which develops, manufactures and sells prescription drugs. It is one of the biggest pharmaceutical companies in the world, with operations in more than 100 countries including China, Mexico, Brazil and Russia.
The company has a large portfolio of products for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. Its range of products include the antibiotic Merrem/Meronem, proton pump inhibitor Losec/Prilosec for treatment of acid related illnesses and other medicines such as Plendil, Onglyza, Symbicort, Zoladex and Onglyza.
AstraZeneca was formed in 1999 through the merger of the Sweden's Astra AB and Zeneca Group of the UK.
The company has a primary listing on the London Stock Exchange where it is a constituent of the FTSE 100 Index. With a market capitalisation of over £40 billion it is one of the biggest companies on the LSE. AstraZeneca has a secondary listing on the New York Stock Exchange, trading under the symbol AZN.
On July 18, 2013 AstraZeneca bought Omthera Pharmaceuticals, a US-based pharmaceutical company. Also in July of the same year it sold its toxicological laboratory in Gartuna to Acturum.